Krystal Biotech is a commercial-stage biotechnology company that discovers, develops, and manufactures genetic medicines using a proprietary engineered herpes simplex virus-1 platform, which efficiently delivers therapeutic genes to cells via non-invasive or minimally invasive administration. The company's lead approved product, VYJUVEK, treats dystrophic epidermolysis bullosa, a rare genetic skin disease, by delivering the COL7A1 gene topically to enable cells to produce normal collagen and address the underlying genetic deficiency. Beyond its commercial dermatology franchise, Krystal is advancing a pipeline of clinical-stage candidates for respiratory conditions, ophthalmology, additional dermatologic indications, oncology, and aesthetics, while leveraging the platform's advantages of repeat dosability, episomal persistence, large payload capacity, and high transduction efficiency to create multiple value-creation opportunities. The company generates revenue through direct commercialization of approved products in major markets and via specialty partnerships, alongside potential future revenues from pipeline candidates and out-licensing collaborations.